rifampicin/isoniazid/ethambutol/pyrazinamide / Generic mfg. - LARVOL DELTA

1H-NMR-based metabolomics study of Rifafour in a healthy Kramnik (C3HeB/FeJ) tuberculosis mouse model. (PubMed, Front Pharmacol) - "That is, these findings highlight the need to distinguish drug-induced metabolic abnormalities from those resulting from infections, consequently aiding the interpretation of metabolomic data in tuberculosis research and improving the development of more accurate therapeutic and diagnostic approaches. Hence, future studies can focus on the perturbed metabolites from TB and account for metabolites resulting from anti-TB medication, as shown in this study."

Journal • Preclinical • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Hepatic disseminated mycobacterium infection: a case report and a literature review. (PubMed, AME Case Rep) - "Following diagnosis, the patient was treated with rifampin, isoniazid, pyrazinamide, ethambutol, and clarithromycin. For patients with multi-organ disseminated infection involving the liver, conventional anti-tuberculosis drugs are less effective, and the infection continues to pose a serious threat that should be considered a high priority. When formulating NTM chemotherapy regimens, combination therapy should be selected based on drug susceptibility testing results, and ongoing monitoring of both drug sensitivity and safety should be ensured throughout the treatment process."

Journal • Gastroenterology • Hepatology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Lower Lobe, Higher Suspicion: An Atypical Presentation of Pulmonary Tuberculosis. (PubMed, Cureus) - "The patient was discharged home on standard RIPE (rifampin, isoniazid, pyrazinamide, ethambutol) therapy for six months and instructed to follow up with his primary care physician. This case highlights the atypical nature of this patient's presentation regarding the location of their TB infection, as well as the absence of traditional risk factors associated with TB. In this case, we will discuss the diagnostic challenges associated with atypical TB cases and how occupational exposures may contribute to the onset, severity, or location of TB infection."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A Rare Case of Hepatic Tuberculosis in an Immunocompetent Patient (ACG 2025) - "Patient was initiated on RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol)...Definitive diagnosis requires liver biopsy showing caseating granulomas.Figure: Figure 1: Abdominal Magnetic Resonance Image confirming5.2 x 3.3 cm heterogenous mass in the liver. Figure 2: Abdominal Magnetic Resonance Image showing complete resolution of hepatic mass"

Clinical • Anesthesia • Cough • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases • Tuberculosis

Unraveling the Diagnosis: Mycobacterial Infection Presenting as Suspected Inflammatory Bowel Disease (ACG 2025) - "She was treated with RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol) and azithromycin for MAC, with symptom resolution. (B) Histology of ileum with active ileitis, ulceration, and non-necrotizing granulomas. (C) AFB stain positive for acid-fast bacilli.​"

Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Respiratory Diseases • Tuberculosis

A RARE CASE OF CONSTRICTIVE TUBERCULOSIS PERICARDITIS IN AN IMMUNOCOMPETENT PATIENT (CHEST 2025) - "Given concern for TB, rifampin, isoniazid, pyrazinamide, ethambutol (RIPE) and colchicine were initiated, and the patient was subsequently discharged. TP is a rare extrapulmonary complication of TB. Early treatment as a result of early diagnosis and clinical suspicion leads to improved patient outcomes. In addition to multidisciplinary care, knowledge of national reference lab capabilities and other available resources is integral to optimizing TB diagnosis and management."

Clinical • Cardiovascular • Cough • Human Immunodeficiency Virus • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

DISSEMINATED MYCOBACTERIAL INFECTION IN THE SETTING OF IDIOPATHIC CD4 LYMPHOCYTOPENIA (CHEST 2025) - "16S rRNA sequencing identified Mycobacterium tilburgii, and the patient began empiric antimycobacterial therapy (with Rifampin, Isoniazid, Pyrazinamide, Ethambutol) along with outpatient Amikacin infusions. Invasive NTM infections continue to be an important consideration in patients presenting with unexplained systemic and GI symptoms as well as weight loss, particularly with diagnostic evidence of immunocompromise. Treatment often remains empiric and based on a limited amount of case reports – additional research is needed to guide diagnosis and choice of therapy for these organisms."

Lymphopenia • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Hypotension • Infectious Disease • Nontuberculous Mycobacterial Disease • Novel Coronavirus Disease • CD4 • CD8

TB OR NOT TB? WITH A PNEUMOTHORAX ON THE SIDE (CHEST 2025) - "Infectious disease initiated fluconazole, rifampin, isoniazid, pyrazinamide, ethambutol pending final AFB culture results. Significant pleural effusion in addition to risk factors with tobacco use should prompt additional studies for underlying malignancy. Although pneumothorax is not a common complication of chest tube placement, this should be a consideration if no improvement is noted."

Congestive Heart Failure • Cough • Heart Failure • Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Respiratory Diseases • Solid Tumor • Thyroid Gland Carcinoma • Tuberculosis

TUBERCULOSIS-IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME WITH WORSENING LYMPHADENOPATHY AND PULMONARY INFILTRATES IN HIV-NEGATIVE, IMMUNOCOMPETENT INDIVIDUAL (CHEST 2025) - "RIPE (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) regimen was initiated, leading to clinical improvement with weight gain...RIPE was therefore continued with added intravenous linezolid and levofloxacin. Prednisone was initiated for suspected TB-IRIS and within two days, symptoms improved, including reduced neck swelling and odynophagia... Identifying clear predictive factors and clinically proven treatment for TB-IRIS can ultimately prevent excessive inflammation and clinical deterioration despite anti-TB treatment. Additional studies are needed to characterize and optimize management of TB-IRIS in HIV-negative, immunocompetent patients."

Clinical • Cough • Immunology • Infectious Disease • Inflammation • Respiratory Diseases • Tuberculosis • CD4

A TENUOUS TRAJECTORY FROM TUBERCULOSIS: A CASE OF TUBERCULOSIS SEPSIS (CHEST 2025) - "Rifampin, isoniazid, pyrazinamide, ethambutol, intravenous levofloxacin, and intravenous vancomycin were initiated 27 hours after presentation. The use of corticosteroids may be considered for tuberculosis sepsis but remains an area of additional study. Prompt initiation of anti-tuberculosis therapy is paramount in reducing sepsis related mortality."

Clinical • Bronchiectasis • Cachexia • Cardiovascular • CNS Disorders • Cough • Diabetes • Gastrointestinal Disorder • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Human Immunodeficiency Virus • Hypotension • Immunology • Infectious Disease • Leukopenia • Metabolic Disorders • Pneumonia • Pulmonary Disease • Pulmonary Embolism • Rare Diseases • Respiratory Diseases • Septic Shock • Tuberculosis • IL2RA • ISG20

THE GREAT MASQUERADER: PULMONARY TUBERCULOSIS MIMICKING MALIGNANCY (CHEST 2025) - "The lung biopsy further confirmed tuberculosis with chronic inflammation and granulomas seen on histologic examination and malignancy was ruled out as there was only benign tissue.Our patient was initially treated with azithromycin and ceftriaxone for suspected pneumonia, the patient continued to have persistent fevers and tachycardia, prompting a switch to piperacillin-tazobactam...Once tuberculosis was confirmed, he was placed airborne precautions and started on anti-TB therapy, including rifampin, isoniazid, pyrazinamide, ethambutol, and pyridoxine... The complexity of pulmonary tuberculosis is seen in this case. The initial negative TB tests and the presence of nodules and pleural effusion shows the importance of a broad differential. This case supports the importance of considering tuberculosis in atypical presentations, particularly in patients from endemic regions, to ensure timely and effective management."

Coronary Artery Disease • Cough • Infectious Disease • Lung Cancer • Oncology • Pneumonia • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Tuberculosis

DISSEMINATED TB MASKING AS ACUTE ABDOMEN, PERFORATE VISCUS, AND MESENTERIC LYMPHADENITIS (CHEST 2025) - "Patient is being treated with rifampin, amikacin, linezolid, and metronidazole while on the ventilator multiple vasopressors, unable to tolerate oral therapy. He will be treated with Rifampin-isoniazid-pyrazinamide-ethambutol therapy as soon as able... Tuberculosis causing abdominal compromise is a diagnostic challenge. Often peritoneal TB mimics other pathologies including malignancy. Physician awareness about this rare manifestation and a high index of suspicion is required prompt diagnosis and management"

Cardiovascular • Cough • Gastrointestinal Disorder • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CRP

The case of cutaneous TB in person living with HIV from Eastern European country of Georgia (EACS 2025) - "Combination therapy with rifampicin/isoniazid/ethambutol/pyrazinamide was started... In HIV-infected patients with chronic skin lesions cutaneous tuberculosis should be considered in the differential diagnosis and appropriate investigations should be performed for the timely diagnosis and treatment of active tuberculosis. Pic.A Pic.2"

Clinical • Human Immunodeficiency Virus • Infectious Disease • Tuberculosis • CD4

MCC124. Medically Challenging Cases 124: Critical Care - Monitor 4 (ASA 2025) - No abstract available

Clinical • Critical care

QI04. MCC Quality Improvement Projects 4: Cardiac Anesthesia - Monitor 4 (ASA 2025) - No abstract available

Anesthesia

MCC84. Medically Challenging Cases 84: Cardiac Anesthesia/Professional Issues - Monitor 4 (ASA 2025) - No abstract available

Clinical • Anesthesia

MCC64. Medically Challenging Cases 64: Cardiac Anesthesia - Monitor 4 (ASA 2025) - No abstract available

Clinical • Anesthesia

MCC44. Medically Challenging Cases 44: Cardiac Anesthesia - Monitor 4 (ASA 2025) - No abstract available

Clinical • Anesthesia

MCC24. Medically Challenging Cases 24: Cardiac Anesthesia - Monitor 4 (ASA 2025) - No abstract available

Clinical • Anesthesia

MCC04. Medically Challenging Cases 4: Cardiac Anesthesia - Monitor 4 (ASA 2025) - No abstract available

Clinical • Anesthesia

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis (clinicaltrials.gov) - P2 | N=127 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ May 2025 | Trial primary completion date: Nov 2024 ➔ May 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Beyond the Usual Suspects: TB Pericarditis as a Cause of Refractory Heart Failure (HFSA 2025) - "In the emergency department, he was hypotensive and in atrial fibrillation with rates in the 140s requiring amiodarone and escalating vasopressor support...He was initiated on RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol) with concurrent inotropic and vasopressor support...Clinicians should maintain suspicion for TB in patients with pericardial effusion and systemic symptoms, particularly with relevant epidemiologic exposures. Early biopsy and targeted therapy may improve outcomes."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Cough • Fatigue • Heart Failure • Hematological Disorders • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia • Tuberculosis

S31PK/PD: Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (clinicaltrials.gov) - P3 | N=53 | Completed | Sponsor: Centers for Disease Control and Prevention | Unknown status ➔ Completed

Trial completion • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study (clinicaltrials.gov) - P2 | N=104 | Terminated | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Jun 2024 ➔ Jun 2025 | Completed ➔ Terminated; Accrual was permanently closed due to futility in the experimental arm on June 22, 2023. Follow-up in the experimental arm was extended to 117 weeks.

Trial completion date • Trial termination • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Thirty Respiratory Limited

New P2 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis